Vertebral compression fracture (VCF) is a challenging and not infrequent complication observed following spine stereotactic body radiation therapy (SBRT). OBJECTIVE: To summarize the data from the multiple studies that have been published, addressing the risk and predictive factors for VCF post-SBRT. METHODS: A systematic literature review was conducted. Studies were selected if they specifically addressed risk factors for post-SBRT VCF in their analyses. RESULTS: A total of 11 studies were identified, reporting both the risk of VCF post-SBRT and an analysis of risk factors based on univariate and multivariate analysis. A total of 2911 spinal segments were treated with a crude VCF rate of 13.9%. The most frequently identified risk factors on multivariate analysis were: lytic disease (hazard ratio [HR] range, 2.76-12.2), baseline VCF prior to SBRT (HR range, 1.69-9.25), higher dose per fraction SBRT (HR range, 5.03-6.82), spinal deformity (HR range, 2.99-11.1), older age (HR range, 2.15-5.67), and more than 40% to 50% of vertebral body involved by tumor (HR range, 3.9-4.46). In the 9 studies that specifically reported on the use of post-SBRT surgical procedures, 37% of VCF had undergone an intervention (range, 11%-60%). CONCLUSION: VCF is an important adverse effect following SBRT. Risk factors have been identified to guide the selection of high-risk patients. Evidence-based algorithms with respect to patient selection and intervention are needed.
ability to deliver differential radiation doses with high precision, such that the involved spinal segment is dose escalated while the spinal cord is kept to a lower tolerant dose, was not possible due to technical limitations. As such, patients were treated with palliative conventional external beam radiotherapy (EBRT) with dose fractionation schemes designed to be safe with respect to normal tissue toxicity yet sufficient to provide short-term pain relief and local tumor control. Over the past 2 decades, advancements in radiation delivery apparatus, image-guidance, treatment planning software, the incorporation of robotics and near-rigid body immobilization devices have resulted in the development of stereotactic body radiation therapy (SBRT) and its application to spinal metastases.
1,2 Spine SBRT represents a rapidly evolving treatment paradigm for patients with spinal metastases. [3] [4] [5] The technical aim of spine SBRT is to deliver 1 to 5 hypofractionated radiation treatments to the spinal metastasis clinical target volume while respecting spinal cord tolerance, with an overall accuracy in treatment delivery of approximately 1 to 2 mm. 2 It is important to note that the biologically effective dose of SBRT can be 2 to 8 times greater than EBRT, depending on the fractionation scheme chosen, and the target consists of both the gross tumor volume as visible on magnetic resonance imaging (MRI) as well as the associated anatomy at risk within the spinal segment. Therefore, if the disease is within the vertebral body, then the entire vertebral body is treated. International consensus contouring guidelines have been published that define treatment volumes for spine SBRT. 6, 7 These are important considerations when understanding spine SBRT toxicity data, in particular the risk of VCF.
The clinical aim of spine SBRT is to improve upon historically poor rates of local tumor control and complete pain relief associated with EBRT, and yield durable long-term results. Several reviews of the literature have been performed, and confirm imaging-based 1-yr local control rates in the order of 80% to 90% for de novo spinal metastases, as salvage for EBRT local failures and as a postoperative treatment. 4, 5, 7, 8 Importantly, these results are also observed in histologies classically considered radioresistant such as renal cell carcinoma. 9 The evidence is still lacking randomized controlled trials (RCT) to confirm superiority of SBRT, and 2 phase 2 and 3 trials should complete and be reported in the next few years (NCT00922974 and NCT02512965). 10, 11 With approximately a decade of published experience and mature data, we have gained a good understanding of the adverse event profile specific to spine SBRT. Acutely, we observe that pain flare occurs with a frequency ranging from 23% to 68%, and it may be more frequent and severe following high dose single fraction SBRT. 12, 13 We have also observed that pain flare can be mitigated or rescued with a short course of dexamethasone. 12 Otherwise, significant acute effects are uncommon and self-limited. With respect to late toxicity, of most concern in the early phase of clinical development was radiation myelopathy (RM). The initial RM cases were analyzed and modeled such that evidence-based tolerance thresholds have been generated to guide safe practice. As a result, RM is again considered a very low risk adverse event if guidelines are adhered to. [14] [15] [16] However, what has arisen as the most significant and potentially frequent adverse effect following spine SBRT is the development of VCF. This adverse event has also been observed both as an acute and late adverse effect. 17, 18 The issue of VCF is major as it puts patients at risk for significant pain, subsequent therapeutic surgical interventions, and brings to the forefront appropriate patient selection for prophylactic fixation. The focus of this review is a summary of the current state of knowledge on VCF following SBRT, and an in-depth analysis of associated predictive factors based on the published literature.
METHODS
A systematic review of the literature was conducted to identify published articles, up to April 2017, that reported on VCF risk and risk factors following spine SBRT. Searches were conducted on PubMed and included the search terms "vertebral fracture sbrt," "vertebral fracture stereotactic body radiotherapy," "vertebral fracture radiosurgery," "fracture spine radiosurgery," "fracture spine stereotactic body radiotherapy," "fracture spine sbrt," "spine sbrt vcf," and "spine radiosurgery vcf." All relevant abstracts were reviewed as were the full associated manuscripts. References contained within these manuscripts were also investigated if related to the search criteria. A flow diagram summarizing this process is outlined in Figure 1 .
Studies were systematically selected if they included both the rate of VCF and an analysis of VCF risk factors. A total of 11 studies were identified that met these criteria. Abstracts without an associated published manuscript were excluded. When further information was required authors were directly contacted for clarification. Data regarding vertebral segments treated, number of fractures reported, and therapeutic surgical interventions performed were extracted from each of the 11 studies.
RESULTS
A total of 11 studies were identified reporting the rate of VCF following SBRT, and an analysis of predictive factors using univariate and multivariate analyses (Table 1) . 9, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] The median survival ranged between 10 and 23 mo, and 1-yr survival rates ranged from 50% to 77%. The median SBRT total dose ranged from 18 to 27 Gy delivered in 1 to 3 fractions. The reported VCF rates ranged from 5.7% to 39%. The median clinical and imaging follow-up ranged between 7.3 and 21.2 mo and 7.4 and 14.9 mo, respectively.
Based on the summary of studies in Table 1 , a total of 2911 spinal segments were treated and 404 fractures reported. This results in a crude risk of 13.9%. The median time to VCF ranged from 1.6 to 3.3 mo except for one study that reported a median time to VCF of 25 mo. If this study is excluded as an outlier, the median time to VCF is 2.6 mo. Nine studies, reporting on 2768 spinal segments treated, specifically differentiated de novo VCF from VCF progression. Three hundred fourteen fractures were observed (11.3%), with 5.6% de novo (range, 3%-20%) and 5.8% fracture progression (range, 2.7%-14.7%). Nine studies specified the percentage of spinal segments with lytic tumor that ranged from 27% to 95% (Table 1) . Ten studies stated the percentage of spinal segments with a baseline fracture that ranged from 17% to 42% (Table 1) .
Nine of the 11 studies in Table 1 specified the number of therapeutic surgical interventions specific to post-SBRT VCF. Of the 353 VCFs identified within these studies, 131 (37.1%) surgical interventions were performed. Sixty-three percent underwent a percutaneous cement augmentation procedure and 37% underwent an open or minimally invasive spinal instrumentation procedure. In 5 of these studies, the indication for intervention was specified and pain was the indication in all but 1 patient. More specifically, Rose et al 17 analyzed median pain scores in patients with VCF progression, and a trend towards statistical significance was noted with worse pain in those with VCF than with no VCF. Similarly, Boehling et al 19 also observed worsening pain scores and increased need for narcotics in those with VCF progression. A summary of those predictive factors observed to be significant on univariate and multivariate analysis (MVA) is presented in Table 1 . On MVA, patient factors found significant were age and spinal misalignment; treatment factors were number of treated levels, dose per fraction and prescription dose to the target volume; and disease-related factors included baseline VCF, lytic tumor, histology, solitary metastasis, >40% of vertebral body occupied by tumor, osteolysis rate, and the Spinal Instability Neoplastic Score (SINS). Table 2 summarizes significant predictors observed on MVA in at least 2 separate studies, and the range with respect to the reported hazard ratio (HR). The most commonly reported risk factors, in order of decreasing frequency, were lytic disease (HR range, 2.76-12.2), baseline VCF (HR range, 1.69-9.25), and high dose per fraction SBRT (HR range, 5.03-6.82).
DISCUSSION
The practice of spine SBRT has evolved into a consistent approach with respect to technique, and over the past 5 to In addition to de novo and progressed VCF, pre-existing VCFs that required surgery beyond 1 wk after SRS were also classified as an event.
318 | VOLUME 83 | NUMBER 3 | SEPTEMBER 2018 www.neurosurgery-online.com 10 yr, we have a well-defined body of literature reporting mature outcomes. With respect to adverse events, the importance of VCF is increasingly highlighted and at the forefront of the field. Traditionally, with conventional palliative EBRT, we quote an approximately 5% risk of VCF with the caveat that follow-up has traditionally not been image based and has been limited to the short term. 27, 28 With spine SBRT, and the routine incorporation of MRI in treatment planning and follow-up, we are observing a higher incidence of VCF than expected, even up to 40%. 17, 18, 24 It is critical for safe practice to understand predictive factors for VCF post-SBRT, and to tailor the risk estimate to the individual patient.
One of the initial fundamental questions was whether the SBRT itself increased the risk of VCF, or was the spinal segment poised to fracture regardless. In a large multi-institutional investigation of spine SBRT related VCF, a dose-complication relationship was observed based on the SBRT dose-per-fraction. A 39% risk of VCF was observed with high dose single fraction SBRT (≥24 Gy), 23% with a dose per fraction of 20 to 23 Gy, and 11% when below 20 Gy. 18 These data supported the initial report of a 39% VCF risk with high dose single fraction SBRT by Rose et al. 17 To further support a lower risk of VCF when the dose per fraction is reduced, a 8.5% 1-yr rate of VCF following 24 Gy in 2 fractions (12 Gy per fraction) was observed in a cohort of 279 spinal segments treated at the Sunnybrook Odette Cancer Center (data unpublished, provided by corresponding author). This fractionation scheme is under evaluation in the ongoing Canadian SC24 Phase 3 RCT comparing SBRT to conventional palliative radiation therapy (NCT02512965). 11 However, it is unclear if the risk of VCF can be further reduced with a more protracted fractionation such as 30 Gy in 5 fractions (6 Gy per fraction), which is also practiced globally. 29 There has yet to be a randomized trial investigating the impact of various SBRT regimens for spinal metastases to determine optimal practice.
An important observation within the series summarized in Table 1 lies in the median time to VCF. Rose et al 17 reported a time of 25 mo, as opposed to 2.5 mo in the multi-institutional VCF study reported by Sahgal et al, 18 and 2.6 mo when summarizing all the studies in Table 1 excluding that from Rose et al. 17 This contrast in time-to-VCF raises important aspects with respect to our understanding of the pathophysiology of SBRTinduced VCF.
First, shortly after SBRT, we hypothesize that an acute intense inflammatory reaction, combined with tumor vascular mediated effects associated with high dose per fraction SBRT and enhanced apoptotic cell-mediated death, may impact the bone matrix resulting in a weakened material more prone to failure leading to an increased risk of VCF. Evidence for an intense inflammatory acute effect is indirectly supported by the observation that pain flare rates are substantial following SBRT-as high as 68% in one series where the methodology was prospective and rigorous with respect to patient data collection. 12 Furthermore, it has been observed that the risk of pain flare is greater following single fraction SBRT in comparison to multifraction SBRT, and can be mitigated or rescued by dexamethasone. 12 With respect to acute tumor response, following brain stereotactic radiosurgery (SRS), indirect evidence based on advanced chemical exchange saturation transfer magnetic resonance (MR) imaging suggests that tumor cell apoptosis occurs soon after treatment. 30 Evidence to support enhanced vascular-mediated effects of SBRT were observed in vivo following liver and lung SBRT in the treatment of colorectal cancer oligometastases. Dubois et al 31 observed an association between plasma ceramide levels increasing days after treatment in responders as opposed to nonresponders. 32 This supports the in vitro work suggesting that the vascular-mediated effects inherent to SBRT are a direct result of enhanced tumor vascular mediated endothelial apoptosis that would not otherwise be observed with conventional EBRT. 33 Perfusion MR imaging research following spine SBRT also indicates dramatic effects on perfusion that again indirectly supports a distinct radiobiology inherent to SBRT. 34 Lastly, histopathology following an acute post-SBRT VCF was shown to consist of relatively few viable melanoma cells in a patient with bulky tumor, and a significant inflammatory infiltrate with hemorrhage. 5 Secondly, with respect to late-onset VCF, a host of physiological and biomechanical factors come into play, but radiation necrosis and an impaired remodeling process is plausible. Radiation has been shown to increase the underlying bone collagen cross-links that act to restrict fibrillary sliding and thus suppress plasticity and intrinsic toughness of the bone. 35 These changes compromise the ability of the vertebral body to handle the physiological load and increase the risk of VCF. Al-Omair et al 36 reported on 2 cases of late post-SBRT-induced VCF (time to VCF were 2-3 yr). Imaging revealed VCF progression and T1 signal changes on the MR, and it was not clear if these were associated with local tumor progression. Biopsy revealed that progressive tissue necrosis and fibrosis were responsible for the changes seen on imaging as opposed to tumor recurrence. 36 An illustrative clinical case of late-onset VCF occurring 15 mo post-SBRT is provided in Figure 2 .
Based on the summary of predictive factors on univariate analyses and MVA described in Table 1 , we can conclude a far greater understanding of patient and tumor-based risk factors associated with SBRT-induced VCF. There is consistency in the observations that could be included in developing decisionmaking tools with respect to which spinal segments are at greatest risk of subsequent VCF and require intervention, even prophylactically. These factors are summarized in Table 2 and consist of lytic disease, baseline VCF, dose per fraction, spinal deformity, age, and >40% to 50% of the vertebral body involved with gross tumor. Mechanistically these factors are within expectations. If the integrity of the vertebral body is compromised by a significant osteolytic tumor burden or already fractured, further destabilization of the remaining bone by high dose radiation would elevate post-SBRT VCF risk. Furthermore, decreasing bone integrity with increasing age and the stress of spinal deformity are also known factors (independent of metastatic involvement) associated with VCF.
Several of the significant predictive factors summarized in Table 1 on either uni-or MVA are incorporated in the SINS tool. 37 SINS represents a categorical classification system to identify patients who are stable, potentially unstable, or frankly mechanically unstable, the latter 2 indicating the need for a consultation with a spine surgeon. Based on this review, baseline fracture, lytic disease, spinal malalignment, >50% vertebral body involvement by tumor, and the overall SINS score have been observed to be predictors of VCF risk. SINS has permeated the oncology literature, resulting in its use to formulate guidelines for patient selection specific to spine SBRT, and has been incorporated within spine SBRT clinical trials to enable proper patient selection. 38 However, SINS is not a panacea of predicting VCF. First and foremost, the symptom of mechanical pain has not been identified as a predictor of VCF yet it is the most important criterion in selecting patients for a surgical stabilization. This observation likely reflects 2 critical points. First, the definition of mechanical pain, as movement or positionally related, is not well understood in the absence of proper training in spine assessment. Second, there is likely a selection bias in the literature such that patients with frank mechanical pain were not included in studies assessing post-SBRT VCF risk, as they typically would have been treated surgically at the outset prior to radiation.
The subjective nature of the assessment of lytic, mixed, or blastic disease is also problematic. Standard MRI used clinically to follow patients cannot determine the volume of bone loss secondary to lytic tumors; a high-resolution spine computed tomography (CT) is the best diagnostic tool in this regard. Furthermore, to score a patient with pure lytic or mixed disease is difficult and imprecise. To improve upon this aspect of SINS, Thibault et al 26 applied a computational semiautomated segmentation process to quantify the amount of lytic and blastic disease within the individual vertebral segments. Based on segmented volume, a lytic disease threshold of ≥11.6% resulted in an odds ratio of 37.4 with respect to predicting VCF. This preliminary work highlights the need for quantified volumetric measures of lytic disease burden. A similar quantitative measure (rather than an arbitrary threshold of 50% of the vertebral body fractured) is needed to characterize baseline VCF and work on this is ongoing.
Despite such opportunities for further refinement, SINS is a step forward in characterizing instability and has been shown to assist in the selection of patients at greater risk of SBRT-induced VCF. We highlight 2 papers to compare and contrast that give insight into the importance of SINS in spine SBRT treatment decision making. Lee et al 24 from the MD Anderson Cancer Center reported VCF in 40.5% of the study's 79 patients. At baseline, 41 patients had a low SINS score (SINS 0-6) indicative of mechanical stability, and 38 patients had a high SINS score (SINS 7-12) indicative of potential mechanical instability. VCF was observed in 17.1% of patients in the low SINS cohort as compared to 65.8% in the high SINS cohort. The utility of SINS was confirmed in their MVA. In addition, symptomatic VCF was observed more frequently in the high SINS cohort. In total, 47% of patients with a VCF underwent a therapeutic surgical intervention. Of the studies summarized in Table 1 , 5 specifically categorized spinal segments treated at baseline with SINS. 9, 18, 21, 24, 26 Based on the 817 spinal segments, 52% were SINS stable, 48% were SINS potentially unstable, and less than 1% were frankly unstable. The crude VCF rate in those SINS stable was 8% and in those potentially unstable was 26%.
In contrast, Gestaut et al 39 reported outcomes for 73 patients treated spine SBRT; however, those with a SINS > 10 and those with pain and >33% of the vertebral body involved with tumor were selected for stabilization pre-SBRT. Of the remaining patients, the VCF rate was only 4% and this is despite the majority having been treated with 20 Gy in a single SBRT fraction. Similarly, a crude VCF rate of 5.7% was observed in a large multiinstitutional study reported by Jawad et al. 23 In that cohort, the median dose was also 20 Gy in a single fraction and 35% of patients underwent pre-SBRT procedures for stabilization.
These studies highlight the potential of pre-SBRT stabilization to mitigate the risk of VCF. At present, there remain several challenges as to the determination of which patients require prophylactic stabilization, and evidence-based algorithms are sorely needed to guide management. The hazard lies in the overtreatment of patients and exposure to risks of a surgical procedure that was not required.
In this review, we observe therapeutic surgical interventions performed in 37% (range, 11%-60%) of post-SBRT VCFs. Similar to our need for understanding the selection of patients requiring prophylactic stabilization, further in-depth analysis is required to understand patient selection for therapeutic surgical intervention. Moreover, a greater understanding of the true rate of intervention is needed; for instance, how many patients needed a therapeutic surgical procedure but refused due to medical factors, oncologic and disease factors (as these patients often have widespread metastatic disease and a limited survival), or did not have financial means to afford the intervention or access to spinal surgeons.
In our practice, if a patient is mechanically unstable and/or suffering mechanical pain, then prophylactic cement augmentation or percutaneous fixation is considered. If not indicated prior to SBRT, then we consider a planned post-SBRT prophylactic intervention for those patients with persistent mechanical pain, a high burden of lytic disease, and/or a baseline VCF. If a painful VCF occurs post-SBRT, then we observe or treat depending on the clinical situation. We recognize that the pain associated with VCF may settle and close observation before initiating stabilization is a reasonable approach. Validated evidencebased algorithms are needed in the decision making for stabilization in the context of SBRT, and will emerge as we continue on this trajectory of maximizing local control while minimizing toxicity for patients with spinal metastases.
Limitations
As a review, there are limitations as to what we can conclude from the data, and one of these includes the multi-institutional nature of the studies that could lead to overlap in the patient populations used to determine statistically significant risk factors. Additionally, only 4 of the 11 studies in Table 1 explicitly excluded tumor progression as a cause of VCF; the rates of VCF noted in the remainder of the studies could be a function of treatment and/or tumor progression.
CONCLUSION
VCF is a challenging complication following spine SBRT. Several risk factors have been identified in this review to enable better selection of patients at greater risk of subsequent VCF. We observe that SINS has potential as an instrument to characterize patients who are mechanically unstable and at a greater risk of post-SBRT VCF. High-level evidence is needed to further our understanding of the utility of pre-SBRT prophylactic interventions, the timing of such interventions, and which intervention is best suited for the clinical case.
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